CD274 and non-small cell lung carcinoma: Furthermore, early clinical studies of combination therapies found that non-small cell lung cancer (NSCLC) patients treated with either DNMT or HDAC inhibitors achieved durable treatment responses when subsequently administered PD1/PD-L1 immune checkpoint inhibitors [27, 28].